Circulating C-X-C Motif Ligand 13 as a Biomarker for Early Predicting Efficacy of Subcutaneous Immunotherapy in Children With Chronic Allergic Rhinitis.
Circulating C-X-C Motif Ligand 13 as a Biomarker for Early Predicting Efficacy of Subcutaneous Immunotherapy in Children With Chronic Allergic Rhinitis.
复制标题
循环 C-X-C 基序配体 13 作为生物标志物，用于早期预测慢性过敏性鼻炎儿童皮下免疫治疗的疗效
DOI：
10.3389/fped.2022.872152
复制
发表时间：
2022
影响因子：
2.6
通讯作者：
Jiang, Weihong
中科院分区：
文献类型：
--
作者：
Cheng, Shenghao;Wen, Sihui;Xie, Shaobing;Zhang, Caixia;Zhang, Hua;Gao, Kelei;Fan, Ruohao;Xie, Zhihai;Jiang, Weihong
C-X-C基序配体13（CXCL 13）和B细胞活化因子（BAFF）已被证实参与炎症性疾病，但它们在变应性鼻炎（AR）中的作用尚不清楚。本研究旨在探讨血清CXCL 13和BAFF在AR中的作用及其作为客观生物标志物预测皮下免疫治疗（SCIT）疗效的临床价值。我们前瞻性招募了90名接受SCIT治疗的AR儿童，并在SCIT前收集了他们的血清标本。对所有患者进行1年随访，并根据疗效将其分为有效组和无效组。比较两组患者血清CXCL 13和BAFF浓度。对52名应答者和26名无应答者的验证队列进一步评估细胞因子，并通过酶联免疫吸附测定（ELISA）测定血清CXCL 13和BAFF水平。80名儿童完成了随访计划，56名儿童被归类为有效组，24名儿童被归类为无效组。有效组血清CXCL 13水平明显高于无效组（P < 0.05）。受试者工作特征（ROC）曲线显示CXCL 13作为生物标志物在预测SCIT反应中的潜在价值。此外，在验证群组中，ELISA结果表明应答者的血清CXCL 13水平比无应答者增加（P < 0.05）。ROC曲线显示血清CXCL 13在预测SCIT疗效方面具有良好的准确性。我们的发现-验证研究表明，循环CXCL 13可能作为一种新的生物标志物来预测儿童AR的SCIT结果。提示CXCL 13参与了AR的病理机制，有助于SCIT的基本治疗机制。
C-X-C motif ligand 13 (CXCL13) and B cell-activating factor (BAFF) are proven to be involved in inflammatory diseases, but their role in allergic rhinitis (AR) remains unclear. The aim of this study was to investigate the role of serum CXCL13 and BAFF in AR and their clinical values as objective biomarkers to predict the efficacy of subcutaneous immunotherapy (SCIT). We prospectively recruited 90 children with AR treated with SCIT and collected their serum specimens before SCIT. One-year follow-up was conducted for all patients, and they were categorized into effective and ineffective groups based on efficacy. The serum concentrations of CXCL13 and BAFF were detected and compared between the two groups. A validation cohort of 52 responders and 26 non-responders were further assessed for both cytokines and serum CXCL13 and BAFF levels were assayed by enzyme-linked immunosorbent assay (ELISA). Eighty children completed the follow-up schedule, and 56 children were categorized into the effective group and 24 children into the ineffective group. The serum levels of CXCL13 in the effective group were clearly higher than those in the ineffective group (P < 0.05). Receiver operating characteristic (ROC) curves revealed the potential values of CXCL13 as a biomarker in predicting the response of SCIT. Further, in the validation cohort, ELISA results demonstrated that serum CXCL13 levels were increased in responders than non-responders (P < 0.05). ROC curves showed good accuracy of serum CXCL13 in predicting the efficacy of SCIT. Our discovery–validation study demonstrated that circulating CXCL13 might serve as a novel biomarker to predict the outcome of SCIT in childhood AR. The findings indicated that CXCL13 was involved in the pathological mechanisms of AR and made help to the fundamental therapeutic mechanism of SCIT.
登录
查看更多内容
影响因子：
--
作者：
Klimek L;Bergmann KC;Biedermann T;Bousquet J;Hellings P;Jung K;Merk H;Olze H;Schlenter W;Stock P;Ring J;Wagenmann M;Wehrmann W;Mösges R;Pfaar O
通讯作者：
Pfaar O
影响因子：
12.4
作者：
Li, J.;Sun, B.;Zhong, N.
通讯作者：
Zhong, N.
影响因子：
4.6
作者：
Liu, Wenlong;Zeng, Qingxiang;Luo, Renzhong
通讯作者：
Luo, Renzhong
影响因子：
6.1
作者：
Groh, N.;von Loetzen, C. S.;Schiller, D.
通讯作者：
Schiller, D.
影响因子：
56.9
作者：
Gowthaman, Uthaman;Chen, Jennifer S.;Eisenbarth, Stephanie C.
通讯作者：
Eisenbarth, Stephanie C.